These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8879382)
21. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
22. [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. Zhou JC Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):215-7. PubMed ID: 8261870 [TBL] [Abstract][Full Text] [Related]
23. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. Parvinen LM; Numminen S Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135 [TBL] [Abstract][Full Text] [Related]
24. [Comparative evaluation of 2 schedules of administration of anti- neoplastic drugs by the CMF protocol in disseminated breast cancer]. Korman DB; Snimshchikov VA; Dobroskok LB; Maslova IA; Mikaélian SG; Pines EV Sov Med; 1991; (3):14-5. PubMed ID: 1882280 [TBL] [Abstract][Full Text] [Related]
25. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538 [TBL] [Abstract][Full Text] [Related]
26. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)]. Mallmann P; Nitschmann S Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172 [No Abstract] [Full Text] [Related]
27. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Howell A; Rubens RD; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Hayward JL; Knight RK; Bulbrook RD Recent Results Cancer Res; 1984; 96():74-89. PubMed ID: 6396780 [No Abstract] [Full Text] [Related]
28. Chemotherapy for breast cancer brain metastases. Fenner MH; Possinger K Onkologie; 2002 Oct; 25(5):474-9. PubMed ID: 12415203 [TBL] [Abstract][Full Text] [Related]
29. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912 [TBL] [Abstract][Full Text] [Related]
30. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Elisaf MS; Nakou K; Liamis G; Pavlidis NA Ann Oncol; 2000 Aug; 11(8):1067-9. PubMed ID: 11038048 [TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapy in breast cancer. Dorr A Curr Opin Oncol; 1990 Dec; 2(6):1049-52. PubMed ID: 2099836 [No Abstract] [Full Text] [Related]
32. The use of mitoxantrone in the treatment of breast cancer. Hainsworth JD Semin Oncol; 1995 Feb; 22(1 Suppl 1):17-20. PubMed ID: 7863347 [No Abstract] [Full Text] [Related]
33. Five-drug therapy in advanced breast cancer: factors influencing toxicity and response. Davis HL; Ramirez G; Ellerby RA; Ansfield FJ Cancer; 1974 Aug; 34(2):239-45. PubMed ID: 4852055 [No Abstract] [Full Text] [Related]
34. [Sequential combination chemotherapy in metastatic cancer of the breast]. Leone BA; Rabinovich MG; Strauss E; Arévalo E Medicina (B Aires); 1984; 44(1):15-22. PubMed ID: 6549523 [No Abstract] [Full Text] [Related]
35. Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. Schrama JG; de Boer MM; Baars JW; Schornagel JH; Rodenhuis S Anticancer Res; 2003; 23(3C):2795-800. PubMed ID: 12926115 [TBL] [Abstract][Full Text] [Related]
36. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
37. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer. Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334 [TBL] [Abstract][Full Text] [Related]
38. [Effects of chemotherapy on the changes of histology and function of the ovary]. Chen J; Jiang S; Li J Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):638-40. PubMed ID: 10806692 [No Abstract] [Full Text] [Related]
39. Raynaud's phenomenon after combined adjuvant chemotherapy for breast cancer. De Angelis R; Silveri F; Bugatti L; Filosa G Chemotherapy; 2003 Sep; 49(5):267-8. PubMed ID: 14504440 [No Abstract] [Full Text] [Related]
40. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. Purdy MH Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]